Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...

AI Quick Read MUMBAI: A day after semaglutide lost patent protection in India, top drugmakers including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences launched generic versions priced 50-90% below the ...

At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

The patent for semaglutide, the drug used in major weight-loss medications like Wegovy and Ozempic has expired. The end of the patent — held by Danish pharmaceutical giant Novo Nordisk — opens the ...

Novo Nordisk's India patent on semaglutide expires this week Move to trigger wave of cheaper generics from local drugmakers Concerns raised about misuse, uneven oversight HYDERABAD, March 19 (Reuters) ...

A massive shake-up is underway in India's obesity and diabetes drug market as the patent for Semaglutide—the key ingredient behind blockbuster drugs—expires. This opens the floodgates for over 40 ...

Novo Nordisk's patent for semaglutide (the active ingredient in Ozempic and Wegovy) expires this week (March 2026). This opens the door for more than 50 branded generic semaglutide products to enter ...

Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...

With 90% of prescriptions in the US filled for generic drugs, there is growing concern that supplies of the medications could be in short supply due to the ongoing situation in the Strait of Hormuz, a ...

To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...